|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005767,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0205341,
umls-concept:C0278601,
umls-concept:C0600688,
umls-concept:C0871261,
umls-concept:C1504389,
umls-concept:C1704632,
umls-concept:C1705294,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1999-10-14
|
|
pubmed:abstractText |
Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of inflammatory breast cancer (IBC) is still poor. In this work, we evaluate response and toxicity of high-dose sequential chemotherapy with repeated blood stem cell (BSC) transplantation administered as initial treatment in 100 women with non-metastatic IBC. Ninety-five patients (five patients were evaluated as non-eligible) of median age 46 years (range 26-56) received four cycles of chemotherapy associating: cyclophosphamide (C) 6 g m(-2) - doxorubicin (D) 75 mg m(-2) cycle 1, C: 3 g m(-2) - D: 75 mg m(-2) cycle 2, C: 3 g m(-2) - D: 75 mg m(-2) - 5 FU 2500 mg m(-2) cycle 3 and 4. BSC were collected after cycle 1 or 2 and reinfused after cycle 3 and 4. rG-CSF was administered after the four cycles. Mastectomy and radiotherapy were planned after chemotherapy completion. Pathological response was considered as the first end point of this trial. A total of 366 cycles of chemotherapy were administered. Eighty-seven patients completed the four cycles and relative dose intensity was respectively 0.97 (range 0.4-1.04) and 0.96 (range 0.25-1.05) for C and D. Main toxicity was haematological with febrile neutropenia ranging from 26% to 51% of cycles; one death occurred during aplasia. Clinical response rate was 90% +/- 6%. Eighty-six patients underwent mastectomy in a median of 3.5 months (range 3-9) after the first cycle of chemotherapy; pathological complete response rate in breast was 32% +/- 10%. All patients were eligible to receive additional radiotherapy. High-dose chemotherapy with repeated BSC transplantation is feasible with acceptable toxicity in IBC. Pathological response rate is encouraging but has to be confirmed by final outcome.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-1588366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-2153434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-2651284,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3127036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3279894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3567926,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3594409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3697997,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3783202,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-3940619,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-6387060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-6999898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7082756,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7507729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7541448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7552616,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7595697,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7874340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-7946584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-8018956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-8501500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-8523055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-8554028,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-8622073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-9164178,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-9164196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-9196145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-9257887,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-9489647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10507769-9816037
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:AudhuyBB,
pubmed-author:BardouV JVJ,
pubmed-author:CostaBB,
pubmed-author:CureHH,
pubmed-author:DelozierTT,
pubmed-author:DelvaRR,
pubmed-author:FabbriGG,
pubmed-author:FerreroJ MJM,
pubmed-author:FeuilhadeFF,
pubmed-author:GuillotAA,
pubmed-author:JacquemierJJ,
pubmed-author:JanvierMM,
pubmed-author:LabatJ PJP,
pubmed-author:LinassierCC,
pubmed-author:MousseauMM,
pubmed-author:PalangiéTT,
pubmed-author:PouillartPP,
pubmed-author:RochéHH,
pubmed-author:RousseauFF,
pubmed-author:ViensPP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
449-56
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10507769-Humans,
pubmed-meshheading:10507769-Breast Neoplasms,
pubmed-meshheading:10507769-Blood Transfusion,
pubmed-meshheading:10507769-Female,
pubmed-meshheading:10507769-Mastectomy,
pubmed-meshheading:10507769-Adult,
pubmed-meshheading:10507769-Bone Marrow Diseases,
pubmed-meshheading:10507769-Adenocarcinoma,
pubmed-meshheading:10507769-Middle Aged,
pubmed-meshheading:10507769-Life Tables,
pubmed-meshheading:10507769-Cyclophosphamide,
pubmed-meshheading:10507769-Fluorouracil,
pubmed-meshheading:10507769-Combined Modality Therapy,
pubmed-meshheading:10507769-Survival Rate,
pubmed-meshheading:10507769-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10507769-Remission Induction
|
